Literature DB >> 15295617

Vaccination with helper-dependent adenovirus enhances the generation of transgene-specific CTL.

A Harui1, M D Roth, S M Kiertscher, K Mitani, S K Basak.   

Abstract

Recombinant adenoviral vectors (AdV) have been used experimentally as vaccines to present antigenic transgenes in vivo. However, administration of first-generation vectors (FG-AdV) is often limited by their induction of antiviral immunity. To address this limitation, helper-dependent vectors (HD-AdV) were developed that lack viral coding regions. While the administration of HD-AdV results in long-term gene expression in vivo, their utility as immunogens has never been examined. Direct vaccination with 10(8) blue-forming units (BFU) of HD-AdV injected into C57BL/6 mice lead to superior transgene-specific CTL and antibody responses when compared to the same amount of a FG-AdV. The antibody responses to viral antigens were high in response to both the vectors. As a mechanism to reduce viral exposure, dendritic cells (DC) were transduced with HD-AdV in vitro and then used as a cell-based vaccine. DC transduced with HD-AdV expressed higher levels of transgene-specific mRNA and up to 1200-fold higher levels of transgene protein than did DC transduced with a FG-AdV. In addition, HD-AdV-transduced DC stimulated superior transgene-specific CTL responses when administered in vivo, an effect that was further enhanced by maturing the DC with LPS prior to administration. In contrast to direct immunization with HD-AdV, vaccination with HD-AdV-transduced DC was associated with limited antibody responses against the AdV. We conclude that HD-AdV stimulates superior transgene-specific immune responses when compared to a FG-AdV, and that immunization with a DC-based vaccine maintains this efficacy while limiting antiviral reactivity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15295617     DOI: 10.1038/sj.gt.3302332

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  7 in total

1.  A new genetic vaccine platform based on an adeno-associated virus isolated from a rhesus macaque.

Authors:  Jianping Lin; Roberto Calcedo; Luk H Vandenberghe; Peter Bell; Suryanarayan Somanathan; James M Wilson
Journal:  J Virol       Date:  2009-10-07       Impact factor: 5.103

2.  Helper-Dependent Adenoviral Vectors.

Authors:  Amanda Rosewell; Francesco Vetrini; Philip Ng
Journal:  J Genet Syndr Gene Ther       Date:  2011-10-29

3.  Intranasal immunization with a helper-dependent adenoviral vector expressing the codon-optimized fusion glycoprotein of human respiratory syncytial virus elicits protective immunity in BALB/c mice.

Authors:  Yuan-Hui Fu; Jin-Sheng He; Wei Qiao; Yue-Ying Jiao; Ying Hua; Ying Zhang; Xiang-Lei Peng; Tao Hong
Journal:  Virol J       Date:  2013-06-07       Impact factor: 4.099

4.  Gene therapy with helper-dependent adenoviral vectors: current advances and future perspectives.

Authors:  Francesco Vetrini; Philip Ng
Journal:  Viruses       Date:  2010-09-03       Impact factor: 5.818

5.  Reconstitution of huPBL-NSG mice with donor-matched dendritic cells enables antigen-specific T-cell activation.

Authors:  Airi Harui; Sylvia M Kiertscher; Michael D Roth
Journal:  J Neuroimmune Pharmacol       Date:  2010-06-08       Impact factor: 4.147

Review 6.  High-Capacity Adenoviral Vectors: Expanding the Scope of Gene Therapy.

Authors:  Ana Ricobaraza; Manuela Gonzalez-Aparicio; Lucia Mora-Jimenez; Sara Lumbreras; Ruben Hernandez-Alcoceba
Journal:  Int J Mol Sci       Date:  2020-05-21       Impact factor: 5.923

7.  Comparison of replication-competent, first generation, and helper-dependent adenoviral vaccines.

Authors:  Eric A Weaver; Pramod N Nehete; Stephanie S Buchl; Julien S Senac; Donna Palmer; Philip Ng; K Jagannadha Sastry; Michael A Barry
Journal:  PLoS One       Date:  2009-03-31       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.